Parkman Healthcare Partners LLC Liquidia Corp Transaction History

Parkman Healthcare Partners LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.77 - $12.19 $89,354 - $188,774	-15,486 Reduced 13.21%	101,767 $1.22 Million
Q3 2023 Nov 14, 2023	SELL	$6.27 - $8.15 $1.03 Million - $1.34 Million	-163,881 Reduced 58.29%	117,253 $743,000
Q2 2023 Aug 11, 2023	SELL	$6.63 - $9.9 $303,859 - $453,726	-45,831 Reduced 14.02%	281,134 $2.21 Million
Q1 2023 May 12, 2023	BUY	$5.72 - $7.91 $330,461 - $456,984	57,773 Added 21.46%	326,965 $2.26 Million
Q4 2022 Feb 13, 2023	BUY	$4.68 - $6.54 $68,983 - $96,399	14,740 Added 5.79%	269,192 $1.71 Million
Q3 2022 Nov 14, 2022	BUY	$3.73 - $8.39 $949,105 - $2.13 Million	254,452 New	254,452 $1.38 Million

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.